Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable cation-transporting ATPase 13A5 (ATP13A5) is a member of the P5 subfamily of P-type ATPases, a large superfamily of cation and lipid pumps capable of transporting various ions across membranes using ATP hydrolysis[2]. ATP13A5 is implicated in cation (potentially metal ion) transmembrane transport[7], and has been detected in numerous tissues including the central nervous system, bone marrow, adrenal gland, and adipose tissue[3][4]. While there is evidence linking ATP13A5 to cellular proliferation and hypothesized, but not proven, involvement in blood-brain barrier vascular differentiation, its specific physiological and pathological roles remain incompletely characterized[5]. There are currently no approved drugs, established biomarkers, or major disease associations directly tied to ATP13A5 function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable cation-transporting ATPase 13A5 (ATP13A5).